Elghobaier Mohamed Gamal, Levy Issac, Nanavaty Mayank A
Sussex Eye Hospital, University Hospitals Sussex NHS Foundation Trust, Eastern Road, Brighton BN2 5BF, UK.
Ophthalmology Department, Rabin Medical Center, Petach Tikva 4941492, Israel.
J Clin Med. 2025 Jul 2;14(13):4692. doi: 10.3390/jcm14134692.
: To evaluate the efficacy and safety of using the preservative-free topical proxymetacaine hydrochloride (Minims, 0.5% /, Bausch & Lomb, UK) to control postoperative pain after epithelium-off corneal crosslinking (CXL) for keratoconus. : This is an observational study of patients with mild to severe keratoconus who have undergone epithelium-off CXL. CXL was completed by applying dextran-free riboflavin (0.1%) for 10 min (Vibex Rapid; Avedro, Inc.), followed by continuous UV-A light (Avedro KXL system; Avedro, Inc.) for 30 min at an intensity of 3 mW/cm and an energy of 5.4 J/cm. All patients were prescribed postoperative proxymetacaine hydrochloride PRN with an allowed frequency of up to eight times per 24 h for the first 3 days to control postoperative pain. Patients were reviewed at 1-2 weeks postoperatively for a comprehensive examination, including assessment of delayed corneal healing, removal of the bandage contact lens, and recording of subjective symptoms. : There were 223 eyes of 180 patients with a mean age of 24.9 ± 8.6 years (range: 13-38 years). Male patients were 72%. At their planned first postoperative visit, we found no corneal healing abnormalities, such as persistent epithelial defects, epithelial irregularities, or early postoperative stromal haze, in any patient. All patients subjectively reported that proxymetacaine drops helped them to control postoperative pain, particularly in the first 48 h. : None of the patients reported pain after 3 days of using proxymetacaine drops up to eight times a day for the first 3 days. It appears to be a safe and effective solution to control postoperative pain without any complications.
评估使用不含防腐剂的局部盐酸丙美卡因(Minims,0.5%/,博士伦,英国)控制圆锥角膜去上皮角膜交联术(CXL)术后疼痛的疗效和安全性。
这是一项对接受去上皮CXL的轻至重度圆锥角膜患者的观察性研究。通过应用不含右旋糖酐的核黄素(0.1%)10分钟(Vibex Rapid;Avedro公司)完成CXL,随后以3 mW/cm的强度和5.4 J/cm的能量连续照射UV-A光30分钟(Avedro KXL系统;Avedro公司)。所有患者术后按需开具盐酸丙美卡因,前3天允许的使用频率最高为每24小时8次,以控制术后疼痛。术后1-2周对患者进行复查,进行全面检查,包括评估角膜愈合延迟情况、取下绷带式隐形眼镜以及记录主观症状。
共有180例患者的223只眼,平均年龄为24.9±8.6岁(范围:13-38岁)。男性患者占72%。在计划的首次术后随访中,我们未发现任何患者有角膜愈合异常,如持续性上皮缺损、上皮不规则或早期术后基质 haze。所有患者主观报告称丙美卡因滴眼液有助于控制术后疼痛,尤其是在最初的48小时内。
在最初3天每天使用丙美卡因滴眼液最多8次的情况下,3天后没有患者报告疼痛。它似乎是一种安全有效的控制术后疼痛的解决方案,且无任何并发症。